Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Title:
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study
Author:
Lasagna, A. Bergami, F. Lilleri, D. Percivalle, E. Quaccini, M. Alessio, N. Comolli, G. Sarasini, A. Sammartino, J.C. Ferrari, A. Arena, F. Secondino, S. Cicognini, D. Schiavo, R. Lo Cascio, G. Cavanna, L. Baldanti, F. Pedrazzoli, P. Cassaniti, I.